Population bias in somatic measurement of microsatellite instability status. (9th July 2020)

• Record Type: Journal Article
• Authors: Saul, Michelle; Poorman, Kelsey; Tae, Hongseok; Vanderwalde, Ari; Stafford, Phillip; Spetzler, David; Korn, Wolfgang M.; Gatalica, Zoran; Swensen, Jeff
• Is Part Of: Cancer medicine. Volume 9:Number 17(2020)
• Page Start: 6452
• Page End: 6460
• Publication Date: 2020-07-09
• Subjects: checkpoint inhibitor -- DNA mismatch repair -- immunotherapy -- microsatellite instability -- next‐generation sequencing -- population bias -- reference genome -- precision medicine; 616.994005
• DOI: 10.1002/cam4.3294
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Microsatellite instability (MSI) is a key secondary effect of a defective DNA mismatch repair mechanism resulting in incorrectly replicated microsatellites in many malignant tumors. Historically, MSI detection has been performed by fragment analysis (FA) on a panel of representative genomic markers. More recently, using next‐generation sequencing (NGS) to analyze thousands of microsatellites has been shown to improve the robustness and sensitivity of MSI detection. However, NGS‐based MSI tests can be prone to population biases if NGS results are aligned to a reference genome instead of patient‐matched normal tissue. We observed an increased rate of false positives in patients of African ancestry with an NGS‐based diagnostic for MSI status utilizing 7317 microsatellite loci. We then minimized this bias by training a modified calling model that utilized 2011 microsatellite loci. With these adjustments 100% (95% CI: 89.1% to 100%) of African ancestry patients in an independent validation test were called correctly using the updated model. This poses not only a significant technical improvement but also has an important clinical impact on directing immune checkpoint inhibitor therapy. Abstract : This work presents observations of a significant population bias in an NGS‐based MSI test and minimizes this bias using a computational‐based approach. The research poses not only a significant technical improvement to the NGS‐based MSI diagnostic, but has an important clinical impact on directing immune‐check point inhibitor therapy for late‐stage cancer patients of non‐European descent.